Schulz H U, Hartmann M, Steinijans V W, Huber R, Lührmann B, Bliesath H, Wurst W
Department of Angiology and Geriatrics, Medical University Lübeck, Germany.
Int J Clin Pharmacol Ther Toxicol. 1991 Sep;29(9):369-75.
The potential influence of pantoprazole (BY1023/SK&F96022), a newly developed selective inhibitor of the gastric H+,K(+)-ATPase, on therapeutic serum theophylline concentrations was investigated in a crossover study in 8 healthy male volunteers (age 25-30 [median 27] years, body weight 63-80 [median 68] kg). Steady-state serum theophylline concentrations were obtained by a two-step intravenous infusion scheme of approximately 350 mg theophylline each over 0.5 h and subsequently over approximately 10 h, respectively. In the test period, 30 mg pantoprazole were injected over 2 min on 5 consecutive days and theophylline was infused on day 4. In the reference period, placebo was administered i.v. on 2 consecutive days and theophylline on day 1. Serum pantoprazole concentrations were measured up to 12 h, serum theophylline concentrations up to 36 h. Pantoprazole was well tolerated with and without theophylline. There were no clinically relevant changes in blood pressure, heart rate, ECG and routine clinical laboratory parameters. Primary characteristic for confirmative assessment of no interaction was the area under the concentration/time curve (AUC). Lack of interaction in the sense of equivalence was concluded both for theophylline (with and without pantoprazole) and pantoprazole (with and without theophylline), as the 90%-confidence intervals of the AUC-ratio test/reference were within the equivalence range of 0.8 to 1.25. Further explorative analysis of theophylline disposition kinetics revealed this inclusion also for clearance and volume of distribution, but not for the half-life. In the case of pantoprazole, the corresponding 90%-confidence intervals for any of the secondary characteristics clearance, volume of distribution and half-life were within the above mentioned range.(ABSTRACT TRUNCATED AT 250 WORDS)
在一项交叉研究中,对8名健康男性志愿者(年龄25 - 30岁[中位数27岁],体重63 - 80千克[中位数68千克])进行了研究,以探讨新开发的胃H⁺,K⁺-ATP酶选择性抑制剂泮托拉唑(BY1023/SK&F96022)对治疗性血清茶碱浓度的潜在影响。通过两步静脉输注方案获得稳态血清茶碱浓度,第一步在0.5小时内输注约350毫克茶碱,随后在约10小时内分别输注。在测试期,连续5天每天2分钟内注射30毫克泮托拉唑,并在第4天输注茶碱。在参照期,连续2天静脉注射安慰剂,并在第1天输注茶碱。测定血清泮托拉唑浓度至12小时,血清茶碱浓度至36小时。泮托拉唑在有或没有茶碱的情况下耐受性良好。血压、心率、心电图和常规临床实验室参数均无临床相关变化。用于确认无相互作用评估的主要特征是浓度/时间曲线下面积(AUC)。由于AUC比值测试/参照的90%置信区间在0.8至1.25的等效范围内,因此得出茶碱(有和没有泮托拉唑)和泮托拉唑(有和没有茶碱)在等效意义上缺乏相互作用的结论。对茶碱处置动力学的进一步探索性分析表明,清除率和分布容积也包含在其中,但半衰期不包含。对于泮托拉唑,清除率、分布容积和半衰期等任何次要特征的相应90%置信区间均在上述范围内。(摘要截短于250字)